VRTX - Is Crispr Therapeutics' high short interest justifiable?
2024-02-15 13:01:01 ET
More on CRISPR Therapeutics
- Crispr Therapeutics: Investors Bet Against Casgevy Uptake
- Biotech And Pharma Diversification Pays Off
- Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range
- Crispr, Intellia, and Recursion gain as Ark ETFs boost stakes
- Vertex, CRISPR gene therapy approved in EU for sickle cell disease, beta-thalassemia